Literature DB >> 2227275

24-hour intragastric acidity and plasma gastrin after omeprazole treatment and after proximal gastric vagotomy in duodenal ulcer patients.

T Lind1, C Cederberg, M Olausson, L Olbe.   

Abstract

The relationship between suppressed gastric acidity and the increase in plasma gastrin levels after pharmacological and surgical treatment of peptic ulcer disease were compared in this study. Eight patients with chronic duodenal ulcer and referred for proximal gastric vagotomy were studied. 24-hour intragastric acidity and plasma gastrin levels were investigated in the same patients on three consecutive occasions: preentry without any treatment; after 4 weeks of administration of 20 mg of omeprazole daily, and 4-6 months after proximal gastric vagotomy. Intragastric acidity was slightly more reduced by omeprazole (94%) than after proximal gastric vagotomy (78%), with no difference found during the day or night with either. Plasma gastrin levels increased slightly more after proximal gastric vagotomy [284% (median, 2120 pmol.h/L; range, 733-2831 pmol.h/L)] than after omeprazole administration [186% (median, 1586 pmol.h/L; range, 495-2573 pmol.h/L)]. There is strong evidence that the increased plasma gastrin concentration following omeprazole treatment is caused by the reduced intragastric acidity. The slight increase in plasma gastrin concentration following proximal gastric vagotomy despite a lesser reduction in intragastric acidity may be the result of additional effects on gastrin release by the vagotomy. Both treatments resulted in a modest increase in plasma levels of gastrin that were far below the gastrin levels observed in achlorhydric patients, e.g., patients with pernicious anemia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2227275     DOI: 10.1016/0016-5085(90)90462-a

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  12 in total

1.  Does fasting serum gastrin predict gastric acid suppression in patients on proton-pump inhibitors?

Authors:  E S Bonapace; R S Fisher; H P Parkman
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

2.  Omeprazole: gastrin and gastric data (August 1991)

Authors:  R G Berlin
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

Review 3.  Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.

Authors:  L B Barradell; D McTavish
Journal:  Pharmacoeconomics       Date:  1993-06       Impact factor: 4.981

4.  Gastric cancer risk after vagotomy.

Authors:  G Lundegårdh; A Ekbom; J K McLaughlin; O Nyrén
Journal:  Gut       Date:  1994-07       Impact factor: 23.059

Review 5.  Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.

Authors:  D McTavish; M M Buckley; R C Heel
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

6.  Duodenal bacterial overgrowth during treatment in outpatients with omeprazole.

Authors:  M Fried; H Siegrist; R Frei; F Froehlich; P Duroux; J Thorens; A Blum; J Bille; J J Gonvers; K Gyr
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

Review 7.  Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. A review and analysis.

Authors:  J W Freston; K Borch; S J Brand; E Carlsson; W Creutzfeldt; R Håkanson; L Olbe; E Solcia; J H Walsh; M M Wolfe
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 8.  Pathophysiological effects of long-term acid suppression in man.

Authors:  R F McCloy; R Arnold; K D Bardhan; D Cattan; E Klinkenberg-Knol; P N Maton; R H Riddell; P Sipponen; A Walan
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 9.  Omeprazole. Gastrin and gastric endocrine cell data from clinical studies.

Authors:  R G Berlin
Journal:  Dig Dis Sci       Date:  1991-02       Impact factor: 3.199

10.  Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis.

Authors:  S Cucchiara; R Minella; C Iervolino; M T Franco; A Campanozzi; M Franceschi; F D'Armiento; S Auricchio
Journal:  Arch Dis Child       Date:  1993-12       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.